On the other hand, the activation of PPARα reduces weight gain, whereas the inhibition of PPARγ decreases lipogenesis; unfortunately, current anti-obesity agents are not selective effectors for each subunit. Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.